Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

Darren Cline Biography and Net Worth

Director of Pyxis Oncology

Mr. Cline has more than 30 years of experience in the biopharma industry as an accomplished commercial executive. He has collaborated with R&D across in all stages of development across numerous therapeutic areas including oncology. Mr. Cline has held various leadership roles of increasing scale and complexity at industry-leading companies including Amgen, InterMune, Alexion, Seagen and most recently, GW Pharmaceuticals, where he served as Chief Commercial Officer. Mr. Cline served on the Board of Stemline Therapeutics prior to the acquisition by Menarini Group.

What is Darren S. Cline's net worth?: The estimated net worth of Darren S. Cline is at least $138,173.70 as of June 12th, 2018. Mr. Cline owns 72,723 shares of Pyxis Oncology stock worth more than $138,174 as of November 23rd. This net worth estimate does not reflect any other assets that Mr. Cline may own. Learn More about Darren S. Cline's net worth.
How do I contact Darren S. Cline?: The corporate mailing address for Mr. Cline and other Pyxis Oncology executives is , , . Pyxis Oncology can also be reached via phone at 617-221-9059 and via email at [email protected]. Learn More on Darren S. Cline's contact information.
Has Darren S. Cline been buying or selling shares of Pyxis Oncology?: Darren S. Cline has not been actively trading shares of Pyxis Oncology in the last ninety days. Most recently, on Wednesday, December 8th, Darren S. Cline bought 10,000 shares of Pyxis Oncology stock. The stock was acquired at an average cost of $9.39 per share, with a total value of $93,900.00. Learn More on Darren S. Cline's trading history.
Who are Pyxis Oncology's active insiders?: Pyxis Oncology's insider roster includes Thomas Civik (Director), and Darren Cline (Director). Learn More on Pyxis Oncology's active insiders.

Darren S. Cline Insider Trading History at Pyxis Oncology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/8/2021	Buy	10,000	$9.39	$93,900.00

Darren S. Cline Buying and Selling Activity at Pyxis Oncology

Pyxis Oncology Company Overview

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $1.90

$1.89

$2.10

50 Day Range

MA: $3.64

$1.90

$4.74

2 Week Range

Now: $1.90

$1.35

$6.85

Volume

4,138,935 shs

Average Volume

733,823 shs

Market Capitalization

$112.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.27

Trump won. Buy this coin now.

From Weiss Ratings | Ad